Latest GeneThera Inc. Stories
Results from Pharma Finance 2009 ARVADA, Colo., June 16 /PRNewswire-FirstCall/ -- GeneThera, Inc. (OTC: GTHR.PK). GeneThera, as a service and responsibility to our shareholders, is addressing our recent events. GeneThera Inc.
WHEAT RIDGE, Colo., Oct. 27 /PRNewswire-FirstCall/ -- GeneThera, Inc.
GeneThera, Inc. (PINKSHEETS: GTHR) announced today that it is in negotiations with the University of New Mexico for world wide development and distribution rights to a vaccine developed there that is designed to significantly inhibit the carriage and shedding of the E.coli bacteria in cattle.
GeneThera, Inc. (PINKSHEETS: GTHR) announced today that has tendered a new offer for the acquisition of Oxford Biomedica Plc. Commenting on the news GeneThera Chairman Dr. Tony Milici, M.D., Ph.D.
GeneThera, Inc. (PINKSHEETS: GTHR), a molecular biotechnology company focused on the detection and treatment of disease in live animals using state-of-the-art technology, is pleased to issue this informational release to its shareholders.
GeneThera, Inc.'s (PINKSHEETS: GTHA) CEO Dr. Tony Milici, M.D., Ph.D. wanted to provide an update on the company's recent developments to its loyal shareholders and investment community in the United States and abroad. Firstly, none of the fundamentals has changed within the company.
- In medieval musical notation, a sign or neume denoting a shake or trill.